

10/529088

JC17 Rec'd PCT/PTO 24 MAR 2005
PATENT

S/N Unknown

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	DIAMANDIS	Examiner:	Unknown
Serial No.:	Unknown	Group Art Unit:	Unknown
Filed:	Herewith	Docket No.:	11757.83USWO
Title:	METHODS FOR DETECTING PROSTATE CANCER		

CERTIFICATE UNDER 37 CFR 1.10:

"Express Mail" mailing label number: EV 495841959 US
Date of Deposit: March 24, 2005

I hereby certify that this paper or fee is being deposited with the U.S. Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: Mail Stop PCT, Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450.

By: 

Name: David Ortiz

INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(b))

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner. At least some of the references were recently cited in an International Search Report mailed April 14, 2004.

This statement should be considered because it is submitted within three months of the filing date of the above-identified application, which is not an application under 37 C.F.R. § 1.53(d). Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. § 1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided. Enclosed for the Examiner's information is a copy of the International Search Report.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a

10/529088

JC17 Rec'd PCT/PTO 24 MAR 2005

reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.


Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.

Respectfully submitted,

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, MN 55402-0903
(612)332.5300

Dated: March 24, 2005

By: 
Douglas P. Mueller
Reg. No. 30,300

DPM/pjk



Date Mailed: March 24, 2005

Sheet 1 of 1

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 11757.83USWO	Application Number: Unknown 10/529088
	Applicant: DIAMANDIS	
	Filing Date: Herewith	Group Art Unit: Unknown

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	02/097438	December, 2002	WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Nakamura, et al., "Alternative Splicing Isoforms for Hippostasin (PRSS20/KLK11) in Prostate Cancer Cell Lines", The Prostate 49:72-78 (2001)
	Nakamura, et al., "Human Kallikrein 11; A New Biomarker of Prostate Cancer", The Journal of Urology, vol. 167, no.4, Supplement, May, 2002, Abstract
	Yousef, et al., "Expanded Human Tissue Kallikrein Family - A Novel Panel of Cancer Biomarkers", Tumor Biol 2002; 23: 185-192, May 2002
	Diamandis, et al., "Human Tissue Kallikreins: A Family of New Cancer Biomarkers", Clinical Chemistry, 48:8 1198-1205, 2002
	Magklara, et al., "The combination of Human Glandular Kallikrein and Free Prostate-specific Antigen (PSA) Enhances Discrimination Between Prostate Cancer and Benign Prostatic Hyperplasia in Patients with Moderately Increased Total PSA", Clinical Chemistry 45:11 1960-1966 (1999)

23552

PATENT TRADEMARK OFFICE

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	